Regeneron Pharmaceuticals Inc along with the US Department of Health and Human Services works for the treatment of coronavirus. They started their work in February with a determination of finding medicine to cure coronavirus. During the 2018 outbreak of Ebola in Congo, Regeneron quickly developed a promising monoclonal antibody triplet therapy. Now, amid the ongoing coronavirus pandemic, the biotech is at it again.
Regeneron Pharmaceuticals Inc said that it has identified hundreds of antibodies that could potentially treat the coronavirus. Regeneron announced a partnership with the U.S. Department of Health and Human Services to develop a coronavirus treatment last February. pic.twitter.com/2RdgYfdAEa
— GMA Public Affairs (@GMA_PA) March 24, 2020
The company is testing its rheumatoid arthritis drug, Kevzara, with partner Sanofi SA against the corona.
They have found nearly hundreds of useful antibodies for the treatment of coronavirus. So, Regeneron has decided to select the topmost two antibodies to prepare a cocktail therapy for this fatal disease.
The Challenge Behind the Search
All type of corona has a cell surface protein called the spike protein. It helps the virus binds to the host cell for infection. Regeneron’s SARS-CoV-2 antibodies will target the spike protein in an attempt to block the interaction of the virus with the host.
The (COVID-19) coronavirus pandemic poses a unique challenge for healthcare providers. There are no approved treatments for this disease, nor are there any approved vaccines. That has put big drug companies, universities and biotech startups on their hot seat.
Barron’s spoke with Regeneron CEO, Leonard Schleifer on Tuesday morning about the fight against Covid-19. He also talks about how the company’s technology platform is speeding drug discovery, and how to think about the economics of treatments for pandemic diseases. People are looking at antiviral in order to escape from this distasteful state. They have completely shaken due to this corona and self-quarantine.
When the virus gets into the lungs, it causes this massive inflammation. If you control the inflammation, you’ll be able to do something to prevent patients from needing a respirator. This process makes their fever go away. So it’ll be better to create some antibodies in order to stop this inflammation and fever.
The idea of researching and testing the blood from patients who have recovered from COVID-19 as a treatment against the novel coronavirus can make the search for the right antibiotics much easier.